Innovative CAR-T Therapy Successfully Cures Three-Year-Old with Liver Cancer
A three-year-old child with metastatic liver cancer has been successfully treated using an innovative CAR-T cell therapy engineered with dual interleukins.
Liver cancer remains one of the deadliest malignancies worldwide, ranking third in cancer-related mortality. While immunotherapy using CAR-T cell technology has achieved remarkable success in treating blood cancers, its efficacy against solid tumors like liver cancer has historically been severely limited. Researchers have long targeted glypican-3, a protein abundantly expressed on liver cancer cell surfaces but largely absent in healthy tissue, though previous attempts often triggered dangerous side effects.
A clinical breakthrough led by Dr. Andras Heczey at Texas Children's Hospital has successfully treated a three-year-old child suffering from metastatic liver disease. Building upon earlier clinical trials involving 24 patients, where engineered CAR-T cells incorporating interleukin-15 showed tumor reduction but elevated cytokine release syndrome risks, the research team introduced a novel dual-cytokine approach published in the New England Journal of Medicine.
The young patient, who had previously undergone three rounds of chemotherapy and extensive surgeries for liver and lung metastases without success, received engineered CAR-T cells expressing both interleukin-15 and interleukin-21. Within weeks of receiving the modified T-cell infusion, the patient exhibited significant clinical improvement without experiencing adverse side effects. A second dose administered two months later sustained the progress, and follow-up examinations one year post-treatment confirmed the complete disappearance of all metastatic tumors.
Biomarker analysis further corroborated the treatment's efficacy, as the patient's alpha-fetoprotein blood levels plummeted from an alarming 400,000 nanograms per milliliter prior to therapy down to a normal reading of 4.5 nanograms per milliliter within eight weeks, remaining stable thereafter. Additionally, the engineered cells featured an inducible caspase-9 safety switch designed to trigger apoptosis if adverse complications arose, though activating the mechanism proved unnecessary.
